keyword
MENU ▼
Read by QxMD icon Read
search

Bisphosphonates

keyword
https://www.readbyqxmd.com/read/28632656/intramedullary-nail-fixation-of-atypical-femur-fractures-with-bone-marrow-aspirate-concentrate-leads-to-faster-union-a-case-control-study
#1
Andrew J Lovy, Jun S Kim, John Di Capua, Sulaiman Somani, Stephanie Shim, Aakash Keswani, Rohit Hasija, Yangguan Wu, David Joseph, Richard Ghillani
OBJECTIVES: To evaluate bone marrow aspirate concentrate (BMAC) use in the treatment of AFF. DESIGN: Retrospective case control. SETTING: Level 1 trauma center. PATIENTS: Complete AFF, defined according to American Society of Bone and Mineral Research (ASBMR) criteria, from September 2009 to April 2015 with minimum 1-year follow-up. INTERVENTION: Operative treatment with antegrade intramedullary nails...
July 2017: Journal of Orthopaedic Trauma
https://www.readbyqxmd.com/read/28631925/anticancer-activity-of-polyoxometalate-bisphosphonate-complexes-synthesis-characterization-in-vitro-and-in-vivo-results
#2
Amandine Boulmier, Xinxin Feng, Olivier Oms, Pierre Mialane, Eric Rivière, Christopher J Shin, Jiaqi Yao, Tadahiko Kubo, Taisuke Furuta, Eric Oldfield, Anne Dolbecq
We synthesized a series of polyoxometalate-bisphosphonate complexes containing Mo(VI)O6 octahedra, zoledronate, or an N-alkyl (n-C6 or n-C8) zoledronate analogue, and in two cases, Mn as a heterometal. Mo6L2 (L = Zol, ZolC6, ZolC8) and Mo4L2Mn (L = Zol, ZolC8) were characterized by using single-crystal X-ray crystallography and/or IR spectroscopy, elemental and energy dispersive X-ray analysis and (31)P NMR. We found promising activity against human nonsmall cell lung cancer (NCI-H460) cells with IC50 values for growth inhibition of ∼5 μM per bisphosphonate ligand...
June 20, 2017: Inorganic Chemistry
https://www.readbyqxmd.com/read/28631130/new-insights-into-human-farnesyl-pyrophosphate-synthase-inhibition-by-second-generation-bisphosphonate-drugs
#3
D Fernández, R Ramis, J Ortega-Castro, R Casasnovas, B Vilanova, J Frau
Pamidronate, alendronate, APHBP and neridronate are a group of drugs, known as second-generation bisphosphonates (2G-BPs), commonly used in the treatment of bone-resorption disorders, and recently their use has been related to some collateral side effects. The therapeutic activity of 2G-BPs is related to the inhibition of the human Farnesyl Pyrophosphate Synthase (hFPPS). Available inhibitory activity values show that 2G-BPs act time-dependently, showing big differences in their initial inhibitory activities but similar final IC50 values...
June 19, 2017: Journal of Computer-aided Molecular Design
https://www.readbyqxmd.com/read/28630846/chronic-recurrent-multifocal-osteomyelitis-a-case-report-with-atypical-presentation
#4
Miguel Pádua Figueiredo, Marco Pato, Fernando Amaral
INTRODUCTION: Chronic recurrent multifocal osteomyelitis (CRMO) is a rare autoinflammatory condition. The clinical picture consists of sterile osteomyelitis, typically with multiple-site lesions in the metaphysis of long bones and not uncommonly, symmetrical bone involvement. It is a poorly understood entity, whose prognosis, etiology and ideal treatment are still controversial. The authors report a case of unifocal presentation with an atypical location. CASE REPORT: A previously healthy 12-year-old Caucasian girl came to our institution due to progressive pain on her left thigh for the previous 3 months...
January 2017: Journal of Orthopaedic Case Reports
https://www.readbyqxmd.com/read/28629592/measurement-and-clinical-utility-of-%C3%AE-ctx-in-serum-and-plasma
#5
Stephen A P Chubb, Samuel D Vasikaran
Biochemical markers of bone turnover (BTM) are released during bone remodeling and can be measured in blood or urine as noninvasive surrogate markers for the bone remodeling rate. The C-terminal cross-linked telopeptide of type I collagen (βCTX) is released during bone resorption and is specific to bone tissue. Assays have been developed to measure βCTX in blood and in urine; most current use of βCTX measurement for research and in clinical practice is performed on a blood sample. Method-specific differences for serum and plasma βCTX have led to initiatives to standardize or harmonize βCTX commercial assays...
2017: Advances in Clinical Chemistry
https://www.readbyqxmd.com/read/28625337/osteogenesis-imperfecta-a-clinical-update
#6
Symeon Tournis, Anastasia D Dede
Osteogenesis imperfecta (OI) is the most common inherited form of bone fragility and includes a heterogenous group of genetic disorders which most commonly result from defects associated with type 1 collagen. 85%-90% of cases are inherited in an autosomal dominant manner and are caused by mutations in the COL1A1 and COL1A2 genes, leading to quantitative or qualitative defects in type 1 collagen. In the last decade, defects in several other proteins involved in the normal processing of type 1 collagen have been described...
June 8, 2017: Metabolism: Clinical and Experimental
https://www.readbyqxmd.com/read/28624840/do-topical-applications-of-bisphosphonates-improve-bone-formation-in-oral-implantology-a-systematic-review
#7
N Lozano-Carrascal, O Salomó-Coll, F Hernández-Alfaro, S-A Gehrke, J Gargallo-Albiol, J-L Calvo-Guirado
BACKGROUND: The aim of this systematic literature review was to evaluate the feasibility of topical bisphosphonate application for preserving/enhancing alveolar bone in oral implantology. MATERIAL AND METHODS: An electronic search was conducted in the PubMed/Medline, EMBASE, Scopus, Web of knowledge, and Google-Scholar databases for articles dated from January 2000 to December 2016. Two reviewers assessed the quality of the studies independently. RESULTS: A total of 154 abstracts were identified, of which 18 potentially relevant articles were selected; a final total of nine papers were included for analysis...
June 18, 2017: Medicina Oral, Patología Oral y Cirugía Bucal
https://www.readbyqxmd.com/read/28622548/early-bony-changes-associated-with-bisphosphonate-related-osteonecrosis-of-the-jaws-in-rats-a-longitudinal-in-vivo-study
#8
Josy Lorena Peres Vilarinho, Nathália Ferrare, Andreia Maria Rocha Moreira, Helora Freitas Moura, Ana Carolina Acevedo, Sacha Braun Chaves, Nilce Santos Melo, André Ferreira Leite, Sérgio Bruzadelli Macedo, Melissa Paoletti de Souza, Ana Tereza Bittencourt Guimarães, Paulo Tadeu Figueiredo
OBJECTIVE: To evaluate early bony changes in an animal model of Medication-Related Osteonecrosis of the Jaw (MRONJ) at the side of the local trauma and at the contralateral side, comparing with a control group. Bony changes were evaluated by Microcomputed Tomography (MicroCT) at three times points: at baseline (T0), after drug administration (T1) and after dental extraction (T2). DESIGN: Two groups were compared: the experimental group in which zoledronic acid (ZA) was administered (17 rats) and the control group (13 rats)...
June 6, 2017: Archives of Oral Biology
https://www.readbyqxmd.com/read/28620868/osteoporosis-in-children-with-chronic-illnesses-diagnosis-monitoring-and-treatment
#9
REVIEW
Monica Grover, Laura K Bachrach
PURPOSE OF REVIEW: Osteoporosis is an under-recognized complication of chronic illness in childhood. This review will summarize recent literature addressing the risk factors, evaluation, and treatment for early bone fragility. RECENT FINDINGS: Criteria for the diagnosis of pediatric osteoporosis include the presence of low trauma vertebral fractures alone or the combination of low bone mineral density and several long bone fractures. Monitoring for bone health may include screening for vertebral fractures that are common but often asymptomatic...
June 15, 2017: Current Osteoporosis Reports
https://www.readbyqxmd.com/read/28620575/osteoporosis-management-in-ankylosing-spondylitis
#10
Alicia M Hinze, Grant H Louie
Low bone mineral density (BMD) is increasingly recognized as a common comorbid condition in ankylosing spondylitis (AS). As low BMD increases fracture risk, it is important to identify and treat low BMD in patients with AS who have been shown to be at increased risk for fractures above the population normal. Since low BMD occurs early in disease, we screen during the first year of diagnosis with dual energy x-ray absorptiometry (DXA). If patients are found to have osteoporosis by T-score of less than -2.5 or if their Z-score on DXA is more than two standard deviations below the mean, we initiate therapy with bisphosphonates in males and in females who are not planning any future pregnancies...
December 2016: Current Treatment Options in Rheumatology
https://www.readbyqxmd.com/read/28620059/anakinra-in-a-cohort-of-children-with-chronic-nonbacterial-osteomyelitis
#11
Manuela Pardeo, Denise Pires Marafon, Virginia Messia, Maria Carmen Garganese, Fabrizio De Benedetti, Antonella Insalaco
OBJECTIVE: To report efficacy and safety in patients with chronic nonbacterial osteomyelitis (CNO) unresponsive to nonsteroidal antiinflammatory drugs (NSAID) and bisphosphonates and/or glucocorticoids treated with anakinra. METHODS: Nine patients (6 females) with refractory CNO were treated with anakinra for at least 6 months. We recorded, at baseline and after 6 months of treatment, clinical and laboratory features, and number and distribution of bone lesions detected by 99mTc-MDP bone scintigraphy...
June 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28619003/hydroxyapatite-as-a-nanomaterial-for-advanced-tissue-engineering-and-drug-therapy
#12
Juha Tuukkanen, Miho Nakamura
Hydroxyapatite (HAp) is a complicated ceramic material that varies between the way it appears in biological systems and how it is synthesized as various calcium phosphates. HAp varies in chemical composition of substituting atoms, crystallinity, grain size and electrical polarization. HAp can form solid to macro-, micro- and nanoporous structures. Also, particulate HAp can have highly porous structure. HAp can be used as coatings for metal implants in thicknesses from hundreds of microns down to hundreds of nanometers...
June 15, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28618241/use-of-adjuvant-bisphosphonates-and-other-bone-modifying-agents-in-breast-cancer-a-cancer-care-ontario-and-american-society-of-clinical-oncology-clinical-practice-guideline
#13
Sukhbinder Dhesy-Thind, Glenn G Fletcher, Phillip S Blanchette, Mark J Clemons, Melissa S Dillmon, Elizabeth S Frank, Sonal Gandhi, Rasna Gupta, Mihaela Mates, Beverly Moy, Ted Vandenberg, Catherine H Van Poznak
Purpose To make recommendations regarding the use of bisphosphonates and other bone-modifying agents as adjuvant therapy for patients with breast cancer. Methods Cancer Care Ontario and ASCO convened a Working Group and Expert Panel to develop evidence-based recommendations informed by a systematic review of the literature. Results Adjuvant bisphosphonates were found to reduce bone recurrence and improve survival in postmenopausal patients with nonmetastatic breast cancer. In this guideline, postmenopausal includes patients with natural menopause or that induced by ovarian suppression or ablation...
June 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28618161/prevention-of-osteoporotic-refractures-in-regional-australia
#14
Emily Davidson, Alexa Seal, Zelda Doyle, Kerin Fielding, Joe McGirr
OBJECTIVE: Clinical guidelines recommend that patients who sustain a minimal trauma fracture (MTF) should receive a bone mineral density (BMD) scan and bisphosphonate (or equivalent) therapy if diagnosed with osteoporosis. A pilot fracture liaison service (FLS) was implemented in regional NSW to improve adherence to the guidelines. DESIGN: Prospective cohort study with an historical control. SETTING: Primary care. PARTICIPANTS: Control (n = 47) and cohort (n = 93) groups comprised patients consenting to interview who presented with a MTF to the major referral hospital 4 months before and 12 months after FLS implementation respectively...
June 15, 2017: Australian Journal of Rural Health
https://www.readbyqxmd.com/read/28616259/hyperphosphatemia-in-a-patient-with-spinal-cord-injury-who-received-etidronate-for-the-treatment-of-heterotopic-ossification
#15
Sahil Taravati, Ece Cinar, Yesim Akkoc
INTRODUCTION: Heterotopic ossification (HO) is defined as ectopic bone formation around peripheral joints and in soft tissues. HO is a common complication of diseases of the central nervous system, such as spinal cord injury (SCI) and traumatic brain injury. HO is seen in up to 50% of patients with SCI and typically occurs in the first 12 weeks after onset of injury. Although no treatment method is proven to be curative, nonsteroidal anti-inflammatory drugs, irradiation of the involved body part and bisphosphonates are commonly used in the management of HO...
2017: Spinal Cord Series and Cases
https://www.readbyqxmd.com/read/28613988/cost-effectiveness-of-virtual-bone-strength-testing-in-osteoporosis-screening-programs-for-postmenopausal-women-in-the-united-states
#16
Christoph A Agten, Austin J Ramme, Stella Kang, Stephen Honig, Gregory Chang
Purpose To investigate whether assessment of bone strength with quantitative computed tomography (CT) in combination with dual-energy x-ray absorptiometry (DXA) is cost-effective as a screening tool for osteoporosis in postmenopausal women. Materials and Methods A state-transition microsimulation model of osteoporosis for postmenopausal women aged 55 years or older was developed with a lifetime horizon and U.S. societal perspective. All model inputs were derived from published literature. Three strategies were compared: no screening, DXA with T score-dependent rescreening intervals, and a combination of DXA and quantitative CT with different intervals (3, 5, and 10 years) at different screening initiation ages (55-65 years)...
June 14, 2017: Radiology
https://www.readbyqxmd.com/read/28612485/renal-impairment-and-use-of-nephrotoxic-agents-in-patients-with-multiple-myeloma-in-the-clinical-practice-setting-in-the-united-states
#17
Yi Qian, Debajyoti Bhowmik, Christopher Bond, Steven Wang, Sam Colman, Rohini K Hernandez, Paul Cheng, Michele Intorcia
Renal impairment is a common complication of multiple myeloma and deterioration in renal function or renal failure may complicate clinical management. This retrospective study in patients with multiple myeloma using an electronic medical records database was designed to estimate the prevalence of renal impairment (single occurrence of estimated glomerular filtration rate [eGFR] <60 mL/min per 1.73 m(2) on or after multiple myeloma diagnosis) and chronic kidney disease (at least two eGFR values <60 mL/min per 1...
June 14, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28612307/atypical-subtrochanteric-fractures-in-korean-hip-fracture-study
#18
Y-K Lee, T-Y Kim, Y-C Ha, S-H Song, J W Kim, H C Shon, J S Chang, K-H Koo
In Korean, atypical subtrochanteric fractures (ASF) were rare. Higher BMI and use of bisphosphonate were significant risk factors of ASF. INTRODUCTION: Recently, ASF have been reported to increase among patients on bisphosphonate. However, the incidence of ASF and the association between ASF and bisphosphonate use have not been well defined in Asian population. Our purposes are (1) to estimate the proportion of ASF among Korean patients with proximal femur fracture and (2) to determine the associated risk factors of ASF in the Korean patients...
June 14, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28611279/selective-inhibition-of-matrix-metalloproteinase-2-in-the-multiple-myeloma-bone-microenvironment
#19
Gemma Shay, Marilena Tauro, Fulvio Loiodice, Paolo Tortorella, Daniel M Sullivan, Lori A Hazlehurst, Conor C Lynch
Multiple myeloma is a plasma cell malignancy that homes aberrantly to bone causing extensive skeletal destruction. Despite the development of novel therapeutic agents that have significantly improved overall survival, multiple myeloma remains an incurable disease. Matrix metalloproteinase-2 (MMP-2) is associated with cancer and is significantly overexpressed in the bone marrow of myeloma patients. These data provide rationale for selectively inhibiting MMP-2 activity as a multiple myeloma treatment strategy...
May 23, 2017: Oncotarget
https://www.readbyqxmd.com/read/28608925/osteoradionecrosis-of-the-mandible-in-patients-with-oropharyngeal-carcinoma-treated-with-intensity-modulated-radiotherapy
#20
Francesca Caparrotti, Shao Hui Huang, Lin Lu, Scott V Bratman, Jolie Ringash, Andrew Bayley, John Cho, Meredith Giuliani, John Kim, John Waldron, Aaron Hansen, Li Tong, Wei Xu, Brian O'Sullivan, Robert Wood, David Goldstein, Andrew Hope
BACKGROUND: Osteoradionecrosis (ORN) of the mandible is a late toxicity affecting patients treated with radiotherapy for head and neck malignancies. To the authors' knowledge, ORN has no standardized grading system and its reporting is based on retrospective findings in heterogeneous patient populations. The rate of ORN in the era of intensity-modulated radiotherapy (IMRT) still is unknown. METHODS: The authors report the incidence of ORN from prospectively collected data regarding 1196 patients who were diagnosed with squamous cell carcinoma of the oropharynx and treated with curative-intent IMRT, with or without concomitant systemic treatment, from January 2005 to December 2014...
June 13, 2017: Cancer
keyword
keyword
1525
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"